A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Carboplatin (Primary) ; L-DOS 47 (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Helix BioPharma
- 14 Jun 2021 According to Helix BioPharma Corp media release, final clinical study report will be completed September 2021
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 02 Apr 2020 According to a Helix BioPharma media release, the study reports are being compiled and an abstract has been submitted to a conference.